WEKO3
アイテム
Carbon Ion Radiotherapy for Liver Cancer
https://repo.qst.go.jp/records/54262
https://repo.qst.go.jp/records/542629b252df3-83d5-4554-bc40-e463392a9c33
| Item type | 会議発表論文 / Conference Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2010-12-14 | |||||
| タイトル | ||||||
| タイトル | Carbon Ion Radiotherapy for Liver Cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_5794 | |||||
| 資源タイプ | conference paper | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Imada, Hiroshi
× Imada, Hiroshi× Yasuda, Shigeo× Yamada, Shigeru× Shinoto, Makoto× Oonishi, Kazuhiko× Kamada, Tadashi× Tsujii, Hirohiko× 今田 浩史× 安田 茂雄× 山田 滋× 篠藤 誠× 大西 和彦× 鎌田 正× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The objective of this paper is to present a summary of a clinical study on carbon ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) conducted from April 1995 to August 2005 at the Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, in Japan. A total of 193 patients with HCC were enrolled in the clinical trial of carbon ion beams. In the first and second phase I/II clinical trials, dose escalation experiments were carried out in incremental steps of 10%, resulting in the confirmation of both the safety and efficacy of short-course regimens of 12, 8 and 4 fractions. Based on the results, a phase II clinical study with fixed fractionation, that is, 52.8 GyE/4 fractions, was performed. A total of 47 patients were treated during this phase II study, which resulted in low toxicity and attained a high local control rate (96%) for 5 years after treatment. The last clinical study was conducted from April 2003 to August 2005 with a more hypofractionated regimen of 2 fractions/2 days, in which 36 patients were safely treated within a dose escalation range from 32.0 GyE to 38.8 GyE. The 2-fraction therapy protocol is continuing under the license of Highly Advanced Medical Technology. There have been no therapy-related deaths and no severe adverse events. We can conclude that, because of the low toxicity and high local control rate, C-ion RT has a promising potential as a new, radical, and minimally invasive therapeutic option for HCC. | |||||
| 書誌情報 |
Proceedings of Japanease-European Joint Symposium on Ion Cancer Therapy and NIRS-KI Joint Symposium on Ion-Radiation Sciences, September 9 & 10-11, 2010 Karolinska University Hospital, Solna Stockholm, Sweden Organized by National Institute of Radiological Sciences, Japan and Karolinska Institute, Sweden 巻 NIRS-M, 号 235, p. 36-43, 発行日 2010 |
|||||
| 出版者 | ||||||
| 出版者 | National Institute of Radiological Sciences | |||||
